Authors' objectives: Chronic lymphocytic leukaemia is a cancer that affects white blood cells called lymphocytes. It causes the body to make large numbers of abnormal lymphocytes that do not work properly and build up in the lymph nodes (glands) and bone marrow. Chronic lymphocytic leukaemia usually affects older people and usually develops slowly. However, the disease develops more quickly and is harder to treat in patients when the lymphocyte cells have certain mutations in their genes called 17p deletion or TP53 mutation. Venetoclax is a new drug for patients with chronic lymphocytic leukaemia with the 17p deletion or TP53 mutation, and it is given as a tablet once a day. If venetoclax is licensed for use in the UK, it could be a new treatment option for patients with chronic lymphocytic leukaemia that may reduce symptoms of the disease and increase survival.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/venetoclax-for-chronic-lymphocytic-leukaemia-with-17p-deletion-or-tp53-mutation/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)